Page 105 - Drug Class Review
P. 105
Drug Effectiveness Review Project
Drugs Authors: Farlow et al. 58 Country: US and Canada To compare efficacy and safety of TAC with placebo in patients with probable AD Setting: 23 centers (21 US and 2 Canada) placebo tacrine NA 20 to 80 mg/d 12 weeks 12 weeks 158 310 Men and women with probable AD based on NINCDS criteria and symptoms for 1 year; MMSE 10-26; age > 50 years; mild to moderate AD; without other significant medical conditions Patients with stroke, tumor, subdural hematoma, hydrocephalus, or VaD Concurrent medications with cognitive properties such as anticholinergics, anticonvulsants, a
Alzheimer Year: 1992 Warner-Lambert Study design: RCT Sample size: 468
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
